Table 1.
Patient characteristics recorded before the start of benralizumab therapy (i.e., at the index date or during the 12 months prior to the index date)
| Characteristics | Evaluable population N = 205 |
|---|---|
| Age at the index date, yrs | 55.8 ± 13.3 |
| Female sex | 126 (61.5%) |
| BMI at the index date, kg/m2 (N = 182) | |
| Under/Normal weight | 70 (38.5%) |
| Overweight | 79 (43.4%) |
| Obese | 33 (18.1%) |
| Smoking status at the index date (N = 195) | |
| Non-smoker | 139 (71.3%) |
| Previous smoker | 50 (25.6%) |
| Current smoker | 6 (3.1%) |
| Age at asthma diagnosis, yrs (N = 203) | 38.9 ± 16.7 |
| Asthma duration at the index date, yrs (N = 203) | 12.4 (6.3–24.6) |
| SEA duration at the index date, yrs (N = 203) | 1.6 (1.0–3.1) |
| Atopy at the index date | 85 (41.5%) |
| Comorbidities at the index date | |
| ≥ 1 current asthma-related condition | 103 (50.2%) |
| Chronic rhinosinusitis | 50 (24.4%) |
| GERD | 43 (21%) |
| Allergic conjunctivitis | 28 (13.7%) |
| Allergic rhinitis | 45 (22%) |
| Other (atopic dermatitis, urticaria, etc.) | 17 (8.3%) |
| ≥ 1 current OCS-related condition | 77 (37.6%) |
| Hypertension | 46 (22.4%) |
| Osteoporosis | 23 (11.2%) |
| Cataract | 12 (5.9%) |
| Anxiety/Depression | 11 (5.3%) |
| Type 2 Diabetes Mellitus | 10 (4.9%) |
| Obstructive sleep apnoea | 10 (4.9%) |
| Cardiovascular disease | 7 (3.4%) |
| Other OCS-related ongoing comorbidities | 19 (9.3%) |
| ≥ 1 other ongoing comorbidities | 35 (17.1%) |
| Thyroid disorders | 8 (3.9%) |
| Bronchiectasis | 6 (2.9%) |
| Blood eosinophil count at the index date, cells/mm3 | 580 (400–850) |
| Total serum IgE at the index date, IU/mL (N = 123) | 289 (85–573) |
| Exacerbations during the 12 months prior to the index date (N = 196) | |
| ≥ 1, any severity | 182 (92.9%) |
| AER | 4.03 |
| ≥ 1 mild | 101 (51.5%) |
| ≥ 1 moderate | 121 (61.7%) |
| ≥ 1 severe | 79 (40.3%) |
| AER | 1.10 |
Data are N (%), mean ± SD, or median (IQR). Unless otherwise stated, the evaluable population included 205 patients
yrs years, BMI body mass index, SEA severe eosinophilic asthma, GERD gastroesophageal reflux disease, OCS oral corticosteroids, AER annual exacerbation rate